Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to continue to optimize conditioning regimens in
high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible
unrelated donors. Specifically, the study will determine whether the addition of fludarabine
to the conditioning regimen previously described by Deeg et al. will permit a reduction in
the CY dose, to a point where sustained hematopoietic engraftment and survival are maintained
(or improved), while the frequency of major regimen-related toxicity (RRT) and early deaths
is reduced.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program